Insmed Incorporated (NASDAQ:INSM) Shares Bought by Acuta Capital Partners LLC

Acuta Capital Partners LLC boosted its stake in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 49.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 107,500 shares of the biopharmaceutical company's stock after acquiring an additional 35,400 shares during the quarter. Insmed accounts for 6.4% of Acuta Capital Partners LLC's holdings, making the stock its 4th largest position. Acuta Capital Partners LLC owned approximately 0.06% of Insmed worth $7,848,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently bought and sold shares of the company. Darwin Global Management Ltd. purchased a new position in shares of Insmed during the 2nd quarter valued at approximately $237,076,000. Clearbridge Investments LLC increased its holdings in Insmed by 76.8% in the second quarter. Clearbridge Investments LLC now owns 1,644,948 shares of the biopharmaceutical company's stock valued at $110,212,000 after buying an additional 714,539 shares in the last quarter. Fiera Capital Corp acquired a new position in shares of Insmed in the second quarter worth about $40,570,000. Farallon Capital Management LLC purchased a new stake in shares of Insmed during the 2nd quarter worth about $38,056,000. Finally, Fred Alger Management LLC acquired a new stake in shares of Insmed during the 2nd quarter valued at about $33,404,000.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on INSM shares. Truist Financial reaffirmed a "buy" rating and issued a $105.00 price target (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. TD Cowen lifted their price target on shares of Insmed from $75.00 to $98.00 and gave the company a "buy" rating in a research note on Friday, August 9th. StockNews.com cut Insmed from a "hold" rating to a "sell" rating in a report on Friday, August 9th. Bank of America raised their target price on Insmed from $84.00 to $86.00 and gave the company a "buy" rating in a research report on Wednesday, October 9th. Finally, Stifel Nicolaus increased their price objective on Insmed from $74.00 to $88.00 and gave the company a "buy" rating in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $83.67.

Insider Buying and Selling at Insmed

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total value of $2,686,612.50. Following the sale, the insider now owns 100,100 shares of the company's stock, valued at $7,157,150. This trade represents a 27.29 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Michael Alexander Smith sold 27,871 shares of the business's stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $74.35, for a total value of $2,072,208.85. Following the transaction, the insider now directly owns 67,856 shares of the company's stock, valued at approximately $5,045,093.60. This represents a 29.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 78,882 shares of company stock valued at $5,765,446 in the last 90 days. Company insiders own 4.60% of the company's stock.

Insmed Trading Up 0.3 %

Shares of INSM stock traded up $0.20 on Thursday, hitting $75.88. The stock had a trading volume of 1,018,230 shares, compared to its average volume of 2,230,730. The company's 50 day moving average price is $72.16 and its 200-day moving average price is $67.34. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $80.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The firm has a market capitalization of $13.57 billion, a P/E ratio of -13.67 and a beta of 1.12.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.19) by ($0.08). The business had revenue of $93.40 million for the quarter, compared to the consensus estimate of $93.36 million. Insmed's revenue for the quarter was up 18.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.10) EPS. Analysts anticipate that Insmed Incorporated will post -5.42 earnings per share for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.